Precision Medicine

Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.

CDS: It’s About Process, Not Just Tools

Synonymous with alerts, clinical decision support is more than just tools to execute evidence-based care but also processes.

Thumbnail

Bedside Tablets: Putting Care in Patients’ Hands

Pilot projects focused on specific patient populations are allowing for greater patient engagement and outcomes.

Thumbnail

Paving the Way for Interoperability

Now that so many providers are using EHRs, it’s time for a solid plan to get the systems to communicate and share information.

Thumbnail

Top IT Priorities in 2015: Bang for the Invested Buck

Hospital CIOs and CMIOs share their top priorities for the new year.

ONC unveils interoperability roadmap, first-ever standards advisory

The Office of the National Coordinator for Health Information Technology has issued its highly-anticipated roadmap for interoperability.

Thumbnail

AHA applauds 21st Century Cures but wants more

The draft proposal from House Energy and Commerce Committee--the 21st Century Cures initiative, released Jan. 27--includes telehealth policies but the American Hospital Association (AHA) is pushing for more.

Thumbnail

Medical tourism, a growing phenomenon

Last year, it is estimated that more than one million U.S. consumers left the country to seek medical treatment abroad, reports CNN.

Global Connected Health M2M Market to Grow at 33.08% CAGR by 2019 Says a New Research Report at ReportsnReports.com

Dallas, Texas, January 28, 2015 -- The Global Connected Health M2M Market report says the market is expected to grow at a CAGR of 33.08% from 2014-2019.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.